Corporate Governance - Board of Directors
Kent Snyder, Chairman of the Board of Directors, has served as a member of our Board of Directors since June 2003, and has held the position of Chairman of the Board of Directors since May 2008. Mr. Snyder was Chief Executive Officer of Senomyx from June 2003 until his retirement as of January 2, 2014. From June 2003 until September 2009 Mr. Snyder was also President of Senomyx. Prior to joining Senomyx, from October 2001 to June 2003, Mr. Snyder was retired. From July 1991 to October 2001, Mr. Snyder held various marketing and sales management positions with Agouron Pharmaceuticals, Inc., a Pfizer company. Mr. Snyder's most recent position was President of Global Commercial Operations, and prior to that Mr. Snyder served as Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder is a member of the Board of Directors of Santarus, Inc., a publicly-held biopharmaceutical company, and VentiRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company. Mr. Snyder received his B.S. from the University of Kansas and his M.B.A. from Rockhurst College.
Stephen A. Block, Esq. has served as a member of our Board of Directors since March 2005. Mr. Block served as Chief Legal Officer and Secretary of International Flavors and Fragrances Inc. (IFF),, a leading creator, manufacturer and seller of flavors and fragrances, from January 1993 until his retirement in December 2003. He was named Senior Vice President, General Counsel and Secretary of IFF in February 2000. During his eleven years at IFF he also led the company's Regulatory Affairs department. Prior to 1993, Mr. Block held various management positions with GAF Corporation, a company specializing in specialty chemicals and building materials, and Celanese Corporation, a company specializing in synthetic fibers, chemicals and plastics. Mr. Block currently serves as an industry consultant and as a member of the Executive Committee, Westlake/Santa Barbara Network, of the Tech Coast Angels, a leading angel investing group. Mr. Block is also a director of ChromaDex Corporation, a reference standards and ingredient supply company, and of several privately held companies. Mr. Block received his B.A. cum laude in Russian Studies from Yale University and his law degree from the Harvard Law School. Mr. Block's background contributes to the Board's understanding of the flavor industry. In addition, Mr. Block contributes his experience in the area of corporate governance and public company financial reporting in his role as a member of multiple Board committees.
Mary Ann Gray, Ph.D., has served as a member of our Board of Directors since September 2010. Since 2003, Dr. Gray has served as President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray currently serves on the Boards of Directors of three other publicly traded biopharmaceutical companies, Dyax Corp., Acadia Pharmaceuticals, Inc., and TetraLogic Pharmaceuticals Corporation. At Dyax she is also the lead independent director. Dr. Gray holds a Ph.D. in pharmacology from the University of Vermont and a B.S. in biology from University of South Carolina. Dr. Gray brings to the Board her experience as a financial analyst and portfolio manager in the biotechnology industry, as well as a background in scientific research. In addition, through her past and current service as a director for other development stage biotechnology companies Dr. Gray expands the Board's exposure to corporate and board governance practices at peer companies.
Tom Erdmann joined our Board of Directors in March 2018. Since June 2016, Mr. Erdmann has served as the General Manager of the Acceligen division of Recombinetics, Inc. From 1981 to 2015, Mr. Erdmann served in various leadership positions at Cargill, Inc., including as VP and Global Director of Specialty Sweeteners, Vice President of Truvia® Stevia Operations Director for Cargill Health & Nutrition, Vice President of Emerging Sweetener Strategy for Cargill Health & Nutrition, and, most recently, as Vice President, PepsiCo Global Account Leader for Cargill Foods, Ingredient and Systems. Mr. Erdmann holds a B.S. in Finance from Indiana University, School of Business. Mr. Erdmann has extensive management, commercial and operational experience in the food, ingredient and sweetener business, as well as a deep understanding of commercial and regulatory issues concerning the Company.
John W. Poyhonen, President and Chief Executive Officer, was promoted to his current position and became a member of our Board of Directors as of January 2, 2014. He joined Senomyx in October 2003 as Vice President and Chief Business Officer; was promoted in April 2004 to Vice President and Chief Financial and Business Officer; was named Senior Vice President, Chief Financial and Business Officer in February 2006; and was promoted to President and Chief Operating Officer in September 2009. From 1996 until October 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, a Pfizer company, most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts at Agouron. Mr. Poyhonen is a director of Heron Therapeutics, Inc., a publicly-held specialty pharmaceutical company. He received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas.
Christopher J. Twomey has served as a member of our Board of Directors since March 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostics company, in March 1990 serving in various roles of increasing responsibility, and most recently serving as Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. At Biosite he was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an audit manager. Mr. Twomey is a director of Cadence Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Twomey holds a B.A. from the University of California at Santa Barbara. Mr. Twomey contributes substantial leadership skills and expertise in accounting and financial reporting that are especially valuable in his role as Chairman of our Audit Committee.
Mr. Stebbins joined our Board of Directors in September 2015. Since September 2006, Mr. Stebbins has served as Management Affiliate for MidOcean Partners, providing industry expertise in the flavor, fragrance and specialty chemical space. In addition, since March, 2006, he has served as the President of The Stebbins Partnership, which provides management consulting services to a wide range of clients. From February 2002 to March 2004, Mr. Stebbins served as President, Flavor Division Worldwide for Symrise AG. Prior to 2002, Mr. Stebbins held various senior management and operating positions at Dragoco, GmbH and Dragoco, Inc. He currently serves as the Non-executive Chairman and director of Agilex Fragrances. Mr. Stebbins previously served on the Board of Governors of the Flavor & Extract Manufacturers Association, or FEMA, from 1987 to 1999. Mr. Stebbins holds a B.S. from Castleton State College.